These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 22749309)

  • 21. A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia.
    Aizawa Y; Ueda K; Komura S; Washizuka T; Chinushi M; Inagaki N; Matsumoto Y; Hayashi T; Takahashi M; Nakano N; Yasunami M; Kimura A; Hiraoka M; Aizawa Y
    Int J Cardiol; 2005 Mar; 99(2):343-5. PubMed ID: 15749201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.
    Novak A; Barad L; Zeevi-Levin N; Shick R; Shtrichman R; Lorber A; Itskovitz-Eldor J; Binah O
    J Cell Mol Med; 2012 Mar; 16(3):468-82. PubMed ID: 22050625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium signaling in human stem cell-derived cardiomyocytes: Evidence from normal subjects and CPVT afflicted patients.
    Zhang XH; Morad M
    Cell Calcium; 2016 Mar; 59(2-3):98-107. PubMed ID: 26725479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling.
    Kirchhefer U; Wehrmeister D; Postma AV; Pohlentz G; Mormann M; Kucerova D; Müller FU; Schmitz W; Schulze-Bahr E; Wilde AA; Neumann J
    J Mol Cell Cardiol; 2010 Jul; 49(1):95-105. PubMed ID: 20302875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.
    Sung RJ; Lo CP; Hsiao PY; Tien HC
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling polymorphic ventricular tachycardia at rest using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Sleiman Y; Souidi M; Kumar R; Yang E; Jaffré F; Zhou T; Bernardin A; Reiken S; Cazorla O; Kajava AV; Moreau A; Pasquié JL; Marks AR; Lerman BB; Chen S; Cheung JW; Evans T; Lacampagne A; Meli AC
    EBioMedicine; 2020 Oct; 60():103024. PubMed ID: 32980690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
    Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
    J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unraveling the mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    Iyer V; Armoundas AA
    Conf Proc IEEE Eng Med Biol Soc; 2006; Suppl():6761-4. PubMed ID: 17959506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CPVT-associated RyR2 mutation G230C enhances store overload-induced Ca2+ release and destabilizes the N-terminal domains.
    Liu Y; Kimlicka L; Hiess F; Tian X; Wang R; Zhang L; Jones PP; Van Petegem F; Chen SR
    Biochem J; 2013 Aug; 454(1):123-31. PubMed ID: 23746327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ryanodine receptor-targeted anti-arrhythmic therapy.
    Wehrens XH; Lehnart SE; Marks AR
    Ann N Y Acad Sci; 2005 Jun; 1047():366-75. PubMed ID: 16093511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential.
    Stutzman MJ; Kim CSJ; Tester DJ; Hamrick SK; Dotzler SM; Giudicessi JR; Miotto MC; Gc JB; Frank J; Marks AR; Ackerman MJ
    Stem Cell Reports; 2022 Sep; 17(9):2023-2036. PubMed ID: 35931078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia.
    Fernández-Velasco M; Rueda A; Rizzi N; Benitah JP; Colombi B; Napolitano C; Priori SG; Richard S; Gómez AM
    Circ Res; 2009 Jan; 104(2):201-9, 12p following 209. PubMed ID: 19096022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes.
    Fukuda M; Yamamoto T; Nishimura S; Kato T; Murakami W; Hino A; Ono M; Tateishi H; Oda T; Okuda S; Kobayashi S; Koseki N; Kyushiki H; Yano M
    Biochem Biophys Res Commun; 2014 May; 448(1):1-7. PubMed ID: 24755079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
    Katz G; Arad M; Eldar M
    Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S4153R is a gain-of-function mutation in the cardiac Ca(2+) release channel ryanodine receptor associated with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.
    Zhabyeyev P; Hiess F; Wang R; Liu Y; Wayne Chen SR; Oudit GY
    Can J Cardiol; 2013 Aug; 29(8):993-6. PubMed ID: 23498838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia.
    Marks AR; Priori S; Memmi M; Kontula K; Laitinen PJ
    J Cell Physiol; 2002 Jan; 190(1):1-6. PubMed ID: 11807805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
    Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
    Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.